GSK has announced a significant acquisition, reaching a deal worth $950 million to purchase 35Pharma, a Canadian biopharmaceutical company with a focus on developing therapies for lung diseases linked to
GSK has announced a significant acquisition, reaching a deal worth $950 million to purchase 35Pharma, a Canadian biopharmaceutical company with a focus on developing therapies for lung diseases linked to






